arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Acumen Pharmaceuticals, Inc.

ABOS
$2.30 ▼ -0.34 (-12.88%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
27 Visible periods
22 Metrics
Peer-ranked Benchmarks
Price Chart
26
Health
Poor
Bearish
auto_awesome

Analytical Summary

Acumen Pharmaceuticals, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $166.2M
Dividend Yield
Revenue Growth
Op. Margin
ROIC -37.2%
FCF / Share $-0.25
Trailing P/E
Price / Book 2.9x
FCF Yield
Debt / Equity 0.55
info Valuation on last close. End-of-day price, Sep 23, 2026.

27-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Net Income Profit after all expenses
$-32.72M
↑ +20.1%
FCF / Share Free cash flow per share
$-0.25
↑ +34.5%
Long-Term Debt Long-term obligations
$11.90M
↓ -29.7%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
4
Financial Health
37
Cash Quality
63

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 7 years · 27 quarters